Details for Patent: 9,387,207
✉ Email this page to a colleague
Title: | 5-HT1A receptor subtype agonist |
Abstract: | The present invention relates to a method of treating a patient suffering from a disorder of the central nervous system associated with 5-HT.sub.1A receptor subtype, comprising as an active ingredient a carbostyril derivative or a salt thereof represented by the formula (1): ##STR00001## wherein the carbon-carbon bond between 3- and 4-positions in the carbostyril skeleton is a single or a double bond. |
Inventor(s): | Jordan; Shaun (Frederick, MD), Kikuchi; Tetsuro (Tokushima, JP), Tottori; Katsura (Kamiita, JP), Hirose; Tsuyoshi (Tokushima, JP), Uwahodo; Yasufumi (Tokushima, JP) |
Assignee: | Otsuka Pharmaceutical Co., Ltd. (Tokyo, JP) |
Filing Date: | Mar 04, 2015 |
Application Number: | 14/637,511 |
Claims: | 1. A method of treating a patient suffering from emesis, motion sickness, or migraine, which comprises administering to said patient a therapeutically effective amount of a carbostyril compound of formula (1), or a pharmaceutically acceptable salt or solvate thereof, wherein said patient is a mammal; ##STR00003## wherein the carbon-carbon bond between 3- and 4-positions in the carbonstyril skeleton is a single or a double bond. 2. The method of claim 1 wherein the carbostyril compound is 7-{4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butoxyl}-3,4-dihydrocarbostyri- l. |